OBJECTIVE： To provide reference for rational use of molecular targeted anti-tumor drugs in the clinic. METHODS： In retrospective survey， the utilization of molecular targeted anti-tumor drugs were statistically analyzed in 25 hospitals from Nanjing area during 2012-2014 in terms of consumption sum， DDDs， DDC and B/A. RESULTS： The consumption sum of molecular targeted anti-tumor drugs increased from 6 169.29 ten thousand yuan in 2012 to 8 813.38 ten thousand yuan， increasing by 42.86％； and then decreased to 8 082.3 ten thousand yuan， decreasing by 8.3％. The consumption sum ratio of single-molecule antibody agent decreased year by year， while that of small-molecule tyrosine kinase inhibitor increased year by year. Rituximab and trastuzumab took up the front in the list of annual consumption sum. Trastuzumab， gefitinib and erlotinib remained the top 3 places in the list of DDDs and were used frequently. DDC of most of molecular targeted anti-tumor drugs kept stable relatively， and the B/A value were more than 1； their consumption sum was well synchronized with DDDs. CONCLUSIONS： The utilization of molecular targeted anti-tumor drugs is reasonable in Nanjing area. The price of drugs greatly influence their utilization.